Although these initial observations probably need to be reproduced in larger case series, the inclusion of BRAF and TERT promoter sequencing when assessing thyroid cancer from ectopic thyroid tissue might be a beneficial strategy – not least as the current recommendations are based on individualized risk assessments. This evidence concerns the gene BRAF and thyroid gland carcinoma.